Mesa Laboratories (MLAB) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Mesa Laboratories (MLAB) is set to announce its Q1 2026 earnings before the market opens on Tuesday, August 5th, with analysts expecting an earnings per share of $2.46 and revenue of $60.45 million.
• The company recently declared a quarterly dividend of $0.16 per share, payable on September 15th, representing an annual yield of 0.83%.
• Insider activity showed significant stock sales, with several executives, including the SVP and CFO, selling shares, resulting in a 45.83% and 4.75% decrease in their ownership, respectively.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) will likely be releasing its Q1 2026 earnings data before the market opens on Tuesday, August 5th. Analysts expect Mesa Laboratories to post earnings of $2.46 per share and revenue of $60.45 million for the quarter.

Mesa Laboratories Trading Up 2.2%

Mesa Laboratories stock opened at $77.26 on Tuesday. The stock has a 50-day moving average of $94.58 and a two-hundred day moving average of $116.50. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.47 and a current ratio of 0.63. Mesa Laboratories has a one year low of $67.95 and a one year high of $155.12. The stock has a market cap of $424.93 million, a PE ratio of -208.81 and a beta of 0.86.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 29th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date of this dividend is Friday, August 29th. Mesa Laboratories's dividend payout ratio (DPR) is presently -172.97%.

Insider Activity at Mesa Laboratories

In related news, SVP Brian David Archbold sold 472 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $97.12, for a total transaction of $45,840.64. Following the completion of the transaction, the senior vice president directly owned 558 shares in the company, valued at approximately $54,192.96. This trade represents a 45.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO John Sakys sold 642 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $97.12, for a total value of $62,351.04. Following the transaction, the chief financial officer owned 12,865 shares of the company's stock, valued at approximately $1,249,448.80. This represents a 4.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,053 shares of company stock worth $296,507. 4.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Mesa Laboratories in the first quarter valued at approximately $335,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Mesa Laboratories by 3.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier's stock valued at $2,370,000 after purchasing an additional 685 shares during the period. Royal Bank of Canada grew its holdings in Mesa Laboratories by 1.2% in the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier's stock valued at $3,652,000 after purchasing an additional 353 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock valued at $364,000 after purchasing an additional 143 shares during the period. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on MLAB. Wells Fargo & Company decreased their price target on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a research note on Friday, May 30th. Wall Street Zen cut Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 30th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.